Sanofi CEO: Making drug data public could hurt investment in EU

06/24/2013 | Reuters

The European Medicines Agency's publication of a draft policy that would make detailed data on drugs publicly available after they are approved could deter crucial investment in Europe, said Chris Viehbacher, CEO of Sanofi and president of the European Federation of Pharmaceutical Industries and Associations. The Pharmaceutical Research and Manufacturers of America has condemned EMA's plans to unveil clinical-trial information, saying it could weaken research incentives and harm business.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL